Atezolizumab (anti-PD-L1)

目录号：A2004         批次号: A200412

打印

Atezolizumab (anti-PD-L1)是人源、IgG1单克隆抗体，阻止PD-L1与PD-1和B7.1的相互作用，但不影响PD-L2与PD-1的相互作用；MW：145 KD。

抗体信息

CAS号 1380723-44-3
配制 100 mM Pro-Ac, 20mM Arg, pH5.0
推荐同型对照 Human IgG1
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
纯度 99%
蛋白浓度 7.293mg/ml
内毒素 ＜1EU/mg

客户使用selleck产品的实验数据

Atezolizumab (anti-PD-L1)在文献中得到引用

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer [ Nat Commun, 2025, 16(1):2374] PubMed: 40064880
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) [ J Transl Med, 2025, 23(1):2] PubMed: 39748404
NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer [ Cancer Immunol Immunother, 2025, 74(4):132] PubMed: 40029463
Combination therapy with expanded natural killer cells and atezolizumab exerts potent antitumor immunity in small cell lung cancer [ Cancer Immunol Immunother, 2025, 74(4):143] PubMed: 40056167
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer [ iScience, 2025, 28(3):111943] PubMed: 40034862
Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9 [ Respir Res, 2025, 26(1):17] PubMed: 39815269
PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47/SHP2/SIRPα/SYK/FcγR signalings in tumor associated macrophages [ Sci Rep, 2025, 15(1):2303] PubMed: 39824849
In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy [ Nat Commun, 2024, 15(1):9723] PubMed: 39521768
Miltefosine reinvigorates exhausted T cells by targeting their bioenergetic state [ Cell Rep Med, 2024, 5(12):101869] PubMed: 39657666
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation [ J Immunother Cancer, 2024, 12(5)e008669] PubMed: 38702145

禁止用于人体及治疗！